MedPath

A study in subjects with impaired glucose tolerance (IGT) to evaluate effects of AO-128 on prevention of type 2 diabetes mellitus (Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group comparison)

Not Applicable
Conditions
Impaired glucose tolerance (IGT)
Registration Number
JPRN-UMIN000001109
Lead Sponsor
Takeda Pharmaceutical Company Limited
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
1782
Inclusion Criteria

Not provided

Exclusion Criteria

1. Patient has a history of diabetes mellitus 2. Patient with serious hepatic or renal disorders

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Progression from IGT to type 2 diabetes mellitus
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath